Parag V. Meswani

Corporate Officer/Principal presso ACADIA PHARMACEUTICALS INC.

Health Technology

Consumer Services

Profilo

Parag V.
Meswani is currently the Senior Vice President-Trofinetide at ACADIA Pharmaceuticals, Inc. Prior to this, he held positions at Biogen, Inc. as the Chief Executive Officer-Commercial Operations, at Spark Therapeutics, Inc. as the Head-US Marketing, and at Sio Gene Therapies, Inc. as the Chief Commercial Officer.
Dr. Meswani has an MBA from The Trustees of Columbia University in The City of New York, an undergraduate and doctorate degree from Ernest Mario School of Pharmacy, and another MBA from Columbia Business School.

Posizioni attive di Parag V. Meswani

Società	Posizione	Inizio
ACADIA PHARMACEUTICALS INC.	Corporate Officer/Principal	01/04/2022

Tutte le posizioni attive di Parag V. Meswani

Precedenti posizioni note di Parag V. Meswani

Società	Posizione	Fine
SIO GENE THERAPIES INC.	Direttore operativo	06/10/2020
BIOGEN INC.	Corporate Officer/Principal	-
SPARK THERAPEUTICS, INC.	Vendite & Marketing	-

Vedi nel dettaglio l'esperienza di Parag V. Meswani

Formazione di Parag V. Meswani

Ernest Mario School of Pharmacy	Doctorate Degree
Columbia Business School	Masters Business Admin

Esperienze
Posizioni ricoperte

Attive

Inattive

Società quotate in Borsa

Aziende private

Vedi nel dettaglio l'esperienza di Parag V. Meswani

Relazioni

Relazioni di 1° grado

Aziende connesse in 1º grado

Uomo

Donna

Amministratori

Dirigenti

Vedi i contatti personali

Società collegate

Società quotate in Borsa	2
BIOGEN INC.	Health Technology
ACADIA PHARMACEUTICALS INC.	Health Technology

Aziende private	2
Sio Gene Therapies, Inc. Sio Gene Therapies, Inc. Pharmaceuticals: MajorHealth Technology Sio Gene Therapies, Inc. is a clinical-stage biopharmaceutical company, which engages in the acquisition, development, and commercialization of gene therapies for neurological diseases. The company was founded on October 31, 2014 and is headquartered in New York, NY.	Health Technology
Spark Therapeutics, Inc. Spark Therapeutics, Inc. BiotechnologyHealth Technology Spark Therapeutics, Inc. engages in the research, development, and commercialization of gene therapies. Its product portfolio intends to treat inherited retinal sickness, liver-mediated, and neurodegenerative diseases. The company was founded by Jean Bennett, Beverly Davidson, Katherine A. High, Jeffrey D. Marrazzo, J. Fraser Wright, and Jennifer Wellman on March 13, 2013 and is headquartered in Philadelphia, PA.	Health Technology

Aziende private